The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Eur J Contracept Reprod Health Care · ISSN (e) 1473-0782 · 51 papers in corpus
review 2026
doi:10.1080/13625187.2026.2695185 ·PMID:42417268

BACKGROUND: Combined oral contraceptives (COC)s, besides offering a reliable and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects. METHODS: While contraceptive use is the primary ind…

rct 2026
doi:10.1080/13625187.2026.2644896 ·PMID:41891123

OBJECTIVE: Endometriosis is a chronic, oestrogen-dependent inflammatory disorder affecting up to 10% of reproductive-age women, associated with pelvic pain, infertility, and reduced quality of life. Emerging evidence implicates the vaginal …

review 2025
doi:10.1080/13625187.2025.2589998 ·PMID:41329046

Endometriosis is a common, chronic disease with a high burden for women, characterised by the implantation of endometrial cells outside the uterus. Many different treatments have been proposed for this disease, mainly hormonal, with the obj…

case-report 2025
doi:10.1080/13625187.2025.2525171 ·PMID:40643903

OBJECTIVE: Progestin-only contraceptives are commonly used in women with contraindications for the use of combined hormonal contraception. They are also important treatment options for medical conditions like endometriosis. Although it is w…

case-report 2025
doi:10.1080/13625187.2025.2514746 ·PMID:40549364

BACKGROUND: This is the first report aimed to evaluate the clinical impact and safety of sequential treatment with relugolix combination therapy (relugolix CT) in women with symptomatic uterine fibroids that were inadequately managed with 5…

rct 2024
doi:10.1080/13625187.2024.2398433 ·PMID:39279689

BACKGROUND: Dienogest (DNG) 2 mg/ethinylestradiol (EE) 0.02 mg is the first low-dose combined oral contraceptive (COC) with a prolonged-release formulation that allows stable plasma concentrations and has high contraceptive efficacy (Pearl …

meta-analysis 2024
doi:10.1080/13625187.2024.2373143 ·PMID:39007750

BACKGROUND: Contraceptive methods are well-established in their ability to prevent pregnancy and increase individual agency in childbearing. Evidence suggests that contraceptives can also be used to treat adverse conditions associated with …

review 2024
doi:10.1080/13625187.2024.2317295 ·PMID:38426312

PURPOSE: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill. METHODS: We conducted a literature search for (review) articles that discussed the health benefits of combined oral c…

meta-analysis 2024
doi:10.1080/13625187.2024.2314298 ·PMID:38426337

PURPOSE: The long-acting reversible contraception progestin subdermal implant (ENG implant) may be effective to improve endometriosis-related symptoms. Since adenomyosis is a histopathological form of endometriosis, we aimed to evaluate the…

observational 2023
doi:10.1080/13625187.2023.2199899 ·PMID:37132337

OBJECTIVE: Primary aim of this study was to investigate endometriosis characteristics of patients with psychiatric conditions or depression. The secondary aim was to study tolerability of dienogest in this context. METHODS: This observatio…

case-report 2023
doi:10.1080/13625187.2023.2216329 ·PMID:37267044

PURPOSE: Laparotomic or hysteroscopic myomectomy, and high-intensity focussed ultrasound (HIFU), can be used in the treatment of Type 2 myomas with a > 50% intramural component. Hysteroscopic electroresection may damage the remaining endome…

observational 2022
doi:10.1080/13625187.2022.2128644 ·PMID:36287190

PURPOSE: The aim of the study was to assess the length of diagnostic delay of symptomatic endometriosis in Italy and analyse the presence of correlations between the socio-demographic status of patients and the clinical characteristics/type…

observational 2022
doi:10.1080/13625187.2022.2067329 ·PMID:35611632

PURPOSE: To collect real-world safety and clinical outcome data on the levonorgestrel-releasing intrauterine system (LNG-IUS) for functional/organic heavy menstrual bleeding (HMB) and dysmenorrhoea in Japanese women (J-MIRAI). MATERIALS AN…

qualitative 2022
doi:10.1080/13625187.2022.2097658 ·PMID:35867527

OBJECTIVES: The purpose of the study was to assess the experiences of male partners of women with endometriosis-associated pain after medical treatment in their everyday lives. METHODS: We conducted a phenomenological study based on semi-s…

review 2022
doi:10.1080/13625187.2022.2112169 ·PMID:36053280

PURPOSE: To review and compare the most recently published recommendations on the investigation and management of abnormal uterine bleeding (AUB). MATERIALS AND METHODS: A descriptive review of recommendations from the American College of …

observational 2022
doi:10.1080/13625187.2021.1934441 ·PMID:34282703

OBJECTIVES: To investigate women's knowledge and attitudes regarding the use of the intrauterine device (IUD) for contraceptive purposes and to explore eventual misconceptions about its benefits, and disadvantages. METHODS: A cross-section…

rct 2020
doi:10.1080/13625187.2020.1725461 ·PMID:32069126

Objectives: The aims of the study were to correlate endometriosis-associated pain, evaluated by visual analogue scale (VAS) scores, with serum levels of etonogestrel (ENG), levonorgestrel (LNG), CA-125 and soluble CD23 in users of the ENG i…

rct 2020
doi:10.1080/13625187.2020.1736546 ·PMID:32191532

Objectives: The aim of the study was to update the results of a previous study published 10 years ago and compare the effect on hyperandrogenism of a newer progestin, dienogest (DNG), in a combined oral contraceptive (COC) formulation with …

other 2020
doi:10.1080/13625187.2020.1731734 ·PMID:32162555

Purpose: To evaluate differences in key outcomes between younger and older women receiving the oral contraceptive oestradiol valerate/dienogest (E2V/DNG).Methods: We conducted a pooled post hoc analysis of primary data from 12 studies of E2…

meta-analysis 2019
doi:10.1080/13625187.2018.1550576 ·PMID:30664383

OBJECTIVE: A systematic review was carried out of studies of women with endometriosis, to examine the evidence for efficacy of the use of hormonal contraception to improve disease-related pain and decrease postoperative risk of disease recu…

observational 2019
doi:10.1080/13625187.2019.1602723 ·PMID:31055972

Objective: Our aim was to study the association between early-life factors and the development of endometriosis. Methods: This case-control study included 440 women with surgically confirmed endometriosis (cases) and 880 women without endom…

meta-analysis 2019
doi:10.1080/13625187.2019.1662391 ·PMID:31550940

Recurrence of endometriosis after conservative surgery is not an uncommon finding. There is no uniformity, however, on what the term 'recurrence' means. Recurrence is variously defined in the literature as the relapse of pain, clinical or i…

rct 2018
doi:10.1080/13625187.2018.1531117 ·PMID:30372645

OBJECTIVE: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg lev…

observational 2018
doi:10.1080/13625187.2018.1539163 ·PMID:30481080

PURPOSE: To examine the fertility experiences of women reporting and not reporting endometriosis in a population-based survey. MATERIALS AND METHODS: A cross-sectional survey among a community sample of 1543 women in Australia. Data were a…

case-report 2018
doi:10.1080/13625187.2018.1501799 ·PMID:30203680

BACKGROUND: The subdermal etonogestrel contraceptive implant has a current approved duration of 3 years. There is, however, recent and strong evidence of its effectiveness for 2 additional years during which no pregnancies were documented. …